For biotech companies developing innovative therapies, regulatory approval is only the first major hurdle. Once a medicine receives marketing authorisation, the real question for patients and healthcare systems becomes: Will it be reimbursed and made available in clinical practice? This is where Health Technology Assessment (HTA) plays a decisive role. Understanding HTA is essential for any biotech – especially US-based companies planning European expansion – because it directly influences market access, pricing, and commercial success.
What is Health Technology Assessment?
Health Technology Assessment is a multidisciplinary, evidence-based process that systematically evaluates the properties, effects, and impacts of a health technology. According to the internationally recognised definition, HTA is a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision-making to promote an equitable, efficient, and high-quality health system.
Health technologies include medicines, medical devices, procedures, diagnostic tests, vaccines, and organisational systems used in healthcare.HTA answers four fundamental questions:
- Does the technology work?
- For whom does it work?
- At what cost?
- How does it compare with existing alternatives?
The goal is to support informed decisions by policymakers, payers, and healthcare providers about the adoption, pricing, reimbursement, and appropriate use of new technologies.
HTA vs Regulatory Approval: A Critical Distinction
Regulatory agencies (FDA in the US, EMA in Europe, MHRA in the UK) focus primarily on quality, safety, and efficacy. They ask: Is the product safe and effective enough to be placed on the market?
HTA bodies go further. They assess relative clinical effectiveness, safety in a broader context, and often economic value. They ask: How does this new technology compare with the current standard of care, and does it represent good value for the healthcare system?
A positive regulatory decision does not guarantee favourable HTA outcomes or reimbursement. Many products approved by the EMA or FDA later face restricted access or delayed uptake because of HTA findings.
Key Domains Evaluated in HTA
HTA is multidimensional. Core domains typically include:
- Clinical effectiveness – How well does the technology work compared with alternatives?
- Safety – What are the risks and adverse effects in real-world use?
- Cost and economic implications – Cost-effectiveness, budget impact, and resource use.
- Patient and organisational aspects – Quality of life, patient experience, and impact on healthcare delivery.
- Ethical, social, and legal considerations – Equity, access, and broader societal effects.
Not every HTA covers all domains equally. Some focus mainly on clinical aspects (relative effectiveness assessments), while others include full economic evaluations.
The HTA Process in Brief
Although processes vary by country, most follow a similar structure:
- Scoping – Defining the research question (often using the PICO framework: Population, Intervention, Comparator, Outcomes).
- Evidence assessment – Systematic review and critical appraisal of clinical and economic data.
- Appraisal – An independent committee considers the evidence alongside other factors and makes a recommendation.
- Decision-making – National authorities decide on reimbursement, pricing, or conditions of use.
- Implementation and potential re-assessment – Monitoring real-world use and updating decisions as new evidence emerges.
The EU HTA Regulation and Its Impact on Biotechs
The European Union’s Health Technology Assessment Regulation (Regulation (EU) 2021/2282), often called the HTAR, represents the most significant change in European market access in decades. It introduces mandatory Joint Clinical Assessments (JCAs) at EU level while leaving pricing and reimbursement decisions with individual Member States.
Rollout timeline
- From January 2025: New oncology medicines and Advanced Therapy Medicinal Products (ATMPs).
- From 2028: Orphan medicines.
- From 2030: All new centrally authorised medicines.
The JCA focuses exclusively on relative clinical effectiveness and relative clinical safety. It produces a single scientific report that Member States must consider in their national HTA processes. Economic evaluation, pricing negotiations, and final reimbursement remain national.
Why This Matters for US Biotech Companies
US biotechs have traditionally prioritised FDA approval and US payer strategies (including ICER reviews). Expanding into Europe under the new HTAR brings several structural changes:
1. Parallel evidence requirements
Companies must now prepare a robust clinical comparative evidence package for the JCA in parallel with the EMA Marketing Authorisation Application. The timelines are tightly linked, leaving limited room for sequential planning.
2. Multiple PICOs and broader comparator expectations
The JCA scoping process consolidates input from up to 27 Member States. This frequently results in multiple PICO questions, including comparators based on real clinical practice (which can include off-label use) rather than solely on regulatory standards. US development programmes often focus on a narrower set of comparators, creating potential evidence gaps.
3. Tight submission windows
After the final assessment scope is communicated, companies typically have 60–100 days to submit a complete JCA dossier. Generating or synthesising additional comparative evidence (including indirect treatment comparisons) at short notice is challenging and resource-intensive.
4. Resource and expertise implications
Smaller US biotechs often lack dedicated European HTA teams. Successfully navigating JCA requires early landscape analysis, systematic literature reviews, methodological expertise in comparative effectiveness, and cross-functional coordination between clinical development, regulatory, medical, and market access functions.
5. National residual complexity
Even with a positive or neutral JCA report, companies must still engage with national HTA bodies (NICE, G-BA, HAS, AIFA, etc.) for full appraisals and pricing negotiations. The JCA reduces duplication of clinical assessment but does not eliminate country-specific requirements.
Opportunities alongside the challenges
A well-prepared JCA can streamline national processes, improve consistency of clinical evidence interpretation across Europe, and provide a strong foundation for subsequent pricing discussions. Early Joint Scientific Consultation (JSC) offers a valuable opportunity to align development plans with European HTA expectations before pivotal trials are finalised.
Practical Guidance for Biotech Companies
- Begin HTA planning early – ideally during Phase 2 or at the latest 18–24 months before planned MAA submission.
- Map potential PICO scenarios across key European markets and stress-test evidence gaps.
- Align clinical trial design and endpoints with both regulatory and HTA needs where feasible.
- Build internal or external capability for systematic evidence synthesis and indirect comparisons.
- Treat European regulatory (EMA/MHRA) and HTA workstreams as integrated rather than sequential.
- Monitor the evolving list of ongoing JCAs and published reports for practical insights.
What This Means For Your Biotech
Health Technology Assessment is the critical bridge between regulatory approval and patient access. For biotechs, particularly those based in the US and planning European launches, mastering HTA is now a core commercial competency. The EU HTA Regulation has raised the bar by centralising clinical assessment while preserving national decision-making on value and price. Companies that invest early in understanding HTA principles, anticipating evidence requirements, and integrating market access considerations into development will be better positioned to achieve timely and sustainable patient access across Europe.
Understanding HTA is no longer a “nice-to-have” for biotechs. It is a strategic necessity for successful global development and commercialisation.